EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gemcitabine release kinetics determines the anticancer and immunomodulatory activity of HPMA copolymer nanomedicines

Kateřina Běhalová, Robert Pola, Natálie Adamcová, Martin Ivančík, Milada Šírová, Irfan B Kilic, Petra Procházková, Petr Kašpárek, Alžběta Bulková, Pavol Lukáč, Luca Vannucci, Blanka Říhová und 2 weitere

Journal of Controlled Release · 2026-11 · 399 · 115396

DOI: 10.1016/j.jconrel.2026.115396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-11. Verfasst von Kateřina Běhalová und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, Prague 4 - Krč 14200, Czech Republic; Faculty of Science, Charles Universi…. Hauptthemen laut MEDLINE: Deoxycytidine, Acrylamides, Antimetabolites, Antineoplastic, Nanoparticles. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, Agentura Pro Zdravotnický Výzkum České Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gemcitabine (Gem) is an effective anticancer drug used for the treatment of various cancers. Nevertheless, its clinical benefit is limited owing to its very short plasma half-life, rapid enzymatic inactivation, and systemic toxicity. Here, we report the design, synthesis, and comprehensive biological evaluation of four N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-bound Gem nanomedicines differing in their linker structure and thereby drug release kinetics. The appropriate design enabled us to prepare polymer nanomedicines with highly prolonged Gem circulation and tumor accumulation. All conjugates exerted cytostatic and pro-apoptotic activity in multiple mouse and human cancer cell lines in vitro, with efficacy inversely correlated with Gem release rate. The nanomedicine with the slowest drug release in plasma showed remarkably prolonged systemic exposure up to 96 h versus 2 h for free Gem upon intravenous administration. The prolonged systemic exposure showed superior therapeutic efficacy across multiple mouse and human tumor models, including significantly inhibited tumor growth, considerably extended survival with complete long-term tumor remission, and reduced lung metastatic burden. Mechanistic studies revealed sustained pro-apoptotic activity of the nanomedicine with transcriptional reprogramming of tumor cells, and profound immunomodulatory effects. Optimization of Gem release rate improved pharmacokinetics and antitumor efficacy as well as favorably reshaped the tumor immune microenvironment. Our findings establish Gem release kinetics as a key determinant of HPMA copolymer-Gem conjugate performance and highlight the translational potential of these nanomedicines for overcoming limitations of conventional Gem therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineAcrylamidesAntimetabolites, AntineoplasticNanoparticlesAnimalsGemcitabineHumansCell Line, TumorDrug LiberationFemaleMiceApoptosisNeoplasmsMethacrylates

Stichwörter der Autor:innen

Antitumor efficacyDrug release kineticsGemcitabineHPMA copolymersImmunomodulationLinker

Substanzen

GemcitabineDeoxycytidineN-(2-hydroxypropyl)methacrylamideAcrylamidesAntimetabolites, Antineoplastichydroxypropyl methacrylateMethacrylates

Autor:innen und Institutionen

  • Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, Prague 4 - Krč 14200, Czech Republic; Faculty of Science, Charles University, Viničná 7, Prague 2 - 128 00, Czech Republic.
  • Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 1888/2, Prague 6 - Břevnov 16200, Czech Republic.
  • Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, Prague 4 - Krč 14200, Czech Republic.
  • Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 1888/2, Prague 6 - Břevnov 16200, Czech Republic. Electronic address: etrych@imc.cas.cz.
  • Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, Prague 4 - Krč 14200, Czech Republic. Electronic address: makovar@biomed.cas.cz.

Förderung

  • European Commission
  • Agentura Pro Zdravotnický Výzkum České Republiky

Zitieren

APA

Běhalová, K., Pola, R., Adamcová, N., Ivančík, M., Šírová, M., Kilic, I. B., Procházková, P., Kašpárek, P., Bulková, A., Lukáč, P., Vannucci, L., Říhová, B., Etrych, T., & Kovář, M. (2026). Gemcitabine release kinetics determines the anticancer and immunomodulatory activity of HPMA copolymer nanomedicines. Journal of Controlled Release, 399, 115396. https://doi.org/10.1016/j.jconrel.2026.115396

Vancouver

Běhalová K, Pola R, Adamcová N, Ivančík M, Šírová M, Kilic IB, et al. Gemcitabine release kinetics determines the anticancer and immunomodulatory activity of HPMA copolymer nanomedicines. Journal of Controlled Release. 2026;399:115396. doi:10.1016/j.jconrel.2026.115396

BibTeX
@article{Bhalov2026,
  author = {Běhalová, Kateřina and Pola, Robert and Adamcová, Natálie and Ivančík, Martin and Šírová, Milada and Kilic, Irfan B and Procházková, Petra and Kašpárek, Petr and Bulková, Alžběta and Lukáč, Pavol and Vannucci, Luca and Říhová, Blanka and Etrych, Tomáš and Kovář, Marek},
  title = {Gemcitabine release kinetics determines the anticancer and immunomodulatory activity of HPMA copolymer nanomedicines},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {399},
  pages = {115396},
  doi = {10.1016/j.jconrel.2026.115396}
}
Kostenlos starten →